TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04584112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m\^2 Q2W administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m\^2 Q2W administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m\^2 Q2W administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: G-CSF support for four doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: G-CSF support for four doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Description: GM-CSF support for four doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Description: GM-CSF support for four doses.
Study: NCT03719872

Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-Operative Transabdominal Ultrasound
Description: Pre-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line

Intervention type: DIAGNOSTIC_TEST
Intervention: Post-Operative Transabdominal Ultrasound
Description: Post-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
Study: NCT04536636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docohexanoic acid
Description: Patients received 650 mg DHA/3 times/wk/post-HD session

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control-No drug
Description: Patients received usual medical care with no DHA
Study: NCT03151265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermaCare Low Back Heat Wrap
Description: The ThermaCare Low Back Heat Wrap, is a continuous, low-level, direct heat therapy. It comes in the form of a heat-pack that is strapped to the low back. Heat is provided for approximately 8-hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermaCare Low Back Heat Wrap
Description: The ThermaCare Low Back Heat Wrap, is a continuous, low-level, direct heat therapy. It comes in the form of a heat-pack that is strapped to the low back. Heat is provided for approximately 8-hours.
Study: NCT03339076

Intervention type: DEVICE
Group type: OTHER
Intervention: M3 MINI CATHETER
Description: Participants in the study are using either a foley catheter or Clean Intermittent Catheter devices to facilitate bladder drainage. The study is an alternative method of facilitating bladder drainage with the M3 Mini Catheter.
Study: NCT03821376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound with Lumason
Description: Following consent, they will undergo contrast enhanced ultrasound of their known renal mass(es). This will be performed at University hospital following intravenous administration of Lumason (2.5 mL per injection, maximum of 2 injections per mass).
Study: NCT03313479

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be given with GS
Study: NCT02874638

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BASE egg protein
Description: 0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA-enriched egg protein
Description: BCAA-enriched egg protein provided as crystalline amino acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: small amount of essential amino acids
Description: essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: large amount of essential amino acids
Description: essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein
Study: NCT01339858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine
Description: NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: matched placebo will be supplied in unmarked capsules. Dosing regimen will be the same as in the N-Acetyl Cysteine arm.
Study: NCT01566669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium
Description: Before incision, patients in Group P (n = 120) receive 40mg of parecoxib IV. Thereafter, parecoxib patients receive 40mg of parecoxib IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Before incision, patients in Group C (n = 120) receive 2 mL of normal saline IV. Thereafter, they receive 2 mL of normal saline IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
Study: NCT02223299

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Tryptophan
Description: 2g/d daily for 30 days
Study: NCT00738010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kneehab
Description: Program of NMES 3 times per day, five days per week for 12 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Poli-Stim
Description: Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Voluntary quadriceps muscle contractions.
Study: NCT03630718

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Intervention
Description: The psychoeducational intervention will be a structured education programme and will consist of informing patients about fatigue dimensions, aetiology and treatments, by helping them to develop strategies to cope with fatigue better and by teaching them to manage the balance between activities and rest.~The construction of the contents of the sessions of this intervention will aim to reduce fatigue via the programme developed by Reif et al. in cancer patients and is composed of 6 sessions of 90 minutes, one session per week. It is a group intervention for 8 patients. For this project, the investigators have reorganised the sessions and their content to fit with an individual format adapted to PBC. This format is more appropriate to take into account the specificity of the manifestation of fatigue for each patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis intervention
Description: The hypnosis intervention will consist of decreasing fatigue and the related distress, and increasing feelings of energy and well-being.~Therefore, each hypnosis exercise will be audiotaped and given to the patient at the end of the session. Patients will be asked to use these recordings as much as they want to help them to manage fatigue. The techniques used are inspired by those used in chronic pain management and fatigue.
Study: NCT01904552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Root Canal Length Measurement Device
Description: Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Root Canal Length Measurement Device
Description: Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file
Study: NCT02354976

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to Omega-3 carboxylic acids (olive oil)
Study: NCT02223299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deplin
Description: 15mg daily for 30 days
Study: NCT02354976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 carboxylic acid
Description: 4 g administered as 4 x 1 g capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 200mg
Description: 200mg capsule administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fenofibrate 200mg
Study: NCT04690387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein
Study: NCT02875587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium gluconate
Description: Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
Study: NCT00519480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be available as an oral tablets.
Study: NCT03932565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T therapy for nectin4-positive malignant solid tumor
Description: The Intravenous minimally invasive surgery combined with intratumoral injection of Nectin4/FAP-targeted the fourth-generation CAR-T cells (expressing IL7 and CCL19, or IL12) are used to treat Nectin4-positive advanced malignant solid tumors, maximally eliminating residual cancer cells and preventing recurrence.
Study: NCT04690387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF as an adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF as an adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF as an adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF as an adjuvant
Study: NCT02223299

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: deplin
Description: 15mg daily for 30 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo A
Description: a sugar-pill that looks like a real medication

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo B
Description: a sugar-pill that looks like a real medication
Study: NCT01165944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide
Description: Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide
Description: Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks
Study: NCT04690387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF as an adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF as an adjuvant
Study: NCT01339078

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plastic stenting
Description: The patients receive plastic stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 3 months, for a total duration of 1 year.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kaffes stenting
Description: The patients receive Kaffes stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 6 months, for a total duration of 1 year.
Study: NCT02759627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic-Assisted Gait Training
Description: There were three intervention arms in this study,~1. Robotic-Assisted Gait Training,~2. Conventional Training,~3. Combined Training.
Study: NCT04000373

Intervention type: DEVICE
Group type: OTHER
Intervention: Ekso GT™ exoskeleton
Description: The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
Study: NCT01117714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Staging for Early Detection of Metastases in Lung Cancer
Description: To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Staging for Early Detection of Metastases in Lung Cancer
Description: To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy
Study: NCT02034617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiMoNid
Description: One LiMoNid observation will be performed on day 1-3 post birth, one in time of discharge, and one in the home when the infant has reached 40 weeks (+/- 2 week). All observations are performed in presence of and in collaboration with the parents with the outspoken aim to guide the parents to learn how to read and respond to their infant' signals
Study: NCT04368182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous C-TCR055
Description: Autologous C-TCR055 administered by intravenous (IV) infusion
Study: NCT02232269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black Coffee

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Coffee

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grapefruit Juice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Felodipine
Study: NCT04188769

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: constant deep pressure applied by an air splint
Description: inflation of the Johnstone air splint gives a constant local deep pression on the hemiplegic arm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: constant deep pressure applied by an air splint
Description: inflation of the Johnstone air splint gives a constant local deep pression on the hemiplegic arm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent deep pressure applied by an air splint
Description: continuous inflation and deflation of the Johnstone air splint gives an intermittent local deep pression on the hemiplegic arm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent deep pressure applied by an air splint
Description: continuous inflation and deflation of the Johnstone air splint gives an intermittent local deep pression on the hemiplegic arm

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: uninflated air splint
Description: no deep pressure applied by the air splint

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: uninflated air splint
Description: no deep pressure applied by the air splint

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: contralateral movement
Description: non-hemiplegic arm is flexed and extended 5 times, with a weight of 5kg in the hand, in order to trigger hypertonia in the hemiplegic arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: contralateral movement
Description: non-hemiplegic arm is flexed and extended 5 times, with a weight of 5kg in the hand, in order to trigger hypertonia in the hemiplegic arm

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: contralateral movement
Description: non-hemiplegic arm is flexed and extended 5 times, with a weight of 5kg in the hand, in order to trigger hypertonia in the hemiplegic arm
Study: NCT02602964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep neuromsucular block
Description: Deep or standard neuromuscular block
Study: NCT03996265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride Controlled-release
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02908698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Total treatment duration: 15 days~Doses are as follows:~5 days daily treatment with 0.75 mg/kg of body weight 5 days daily treatment with 0.5 mg/kg of body weight 5 days daily treatment with 0.25 mg/kg of body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Total treatment duration: 15 days. Doses will appear identical to prednisone arm.
Study: NCT03229239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: corneal stroma implantation
Description: During the operation,implant the corneal stroma to the diseased cornea of keratoconus.
Study: NCT01496690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin Placebo Capsules
Description: Parallel to Active Comparator
Study: NCT02528422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyl-Ghrelin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyl-Ghrelin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyl-Ghrelin
Study: NCT03695406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Program for Fear of Recurrence
Description: An adapted protocol of the Relaxation Response Resiliency Program, a manualized, group-based, multimodal mind body program. Protocol adaptation includes refinement of content and study procedures to target fear of cancer recurrence (FCR) among adult cancer survivors.